Long non-coding RNA CASC 2 reduces sorafenib resistance in hepatocellular carcinoma cells via inhibition of miR-21-mediated PI 3 K / AKT pathways

Rui Huang,Gang Wu,Bo Zheng,Jian Xu
2019-01-01
Abstract:Hepatocellular carcinoma (HCC) is highly resistant to sorafenib treatment. This present study examined the relationship between lncRNA CASC2 expression and sensitivity of HCC cells to sorafenib. By selection and establishment of sorafenib-resistant cell lines, it was found that CASC2 was significantly downregulated in sorafenibresistant HepG2 cells. In addition, overexpression of CASC2 could re-sensitize resistant HCC cells to sorafenib by reducing cell viability and promoting cell apoptosis. Overexpression of CASC2 also enhanced the anti-HCC efficacy of sorafenib in vivo. Dual luciferase reporter assay revealed that CASC2 might function as a competing endogenous RNA (ceRNA) for miR-21. miR-21 overexpression rescued functions induced by CASC2 overexpression in sorafenibresistant HCC cells and might be associated with activation of PI3K/AKT pathways. In summary, this study’s findings show that CASC2 might function as a potential therapeutic target to overcome sorafenib resistance in HCC.
What problem does this paper attempt to address?